Paper Review Records
All Paper Review Records
21 valid samples · Newest publication first
Review days = acceptance date − received date. PDF, DOI, and publisher-page sources are retained.
147
days
Advances in chimeric antigen receptor T (CAR-T) cell therapy and limitations for treating breast cancer requires next generation of CAR-T cells treatment
Authors
Yasir Nawaz; Hafiza Fizzah Riaz; Fouzia Tanvir; Basit NawazShow moreShow less
Affiliations
1. Department of Zoology, Faculty of Life Sciences, University of Okara, Okara, Pakistan; 2. Department of Zoology, The Islamia University of Bahawalpur, Rahim Yar Khan Campus, Pakistan; 3. Department of Chemistry, University of Agriculture Faisalabad, Faisalabad, PakistanShow moreShow less
541
days
Mesenchymal phenotype drives high metabolic tumor volume in pancreatic cancer: integrated transcriptomic and single-cell analysis of tumor-stroma metabolic interactions
Authors
Nan Zhou; Jiahui Yuan; Dajun Du; Xiuqing Wang; Tiantian Yang; Zhijun FengShow moreShow less
Affiliations
1. Department of Medical Oncology, Xinyang Key Laboratory of Oncology, Xinyang Central Hospital, Xinyang Normal University Affiliated Hospital, Xinyang City, China; 2. Department of General Surgery, Institute of Precision Diagnosis and Treatment of Digestive System Tumors, Shenzhen University General Hospital, Shenzhen University, Shenzhen, China; 3. Department of Surgical Oncology, Xinyang Central Hospital, Xinyang Normal University Affiliated Hospital, Xinyang City, China; 4. Clinical Research Unit, The Second Affiliated Hospital, Yuying Children’s Hospital of Wenzhou Medical University, Wenzhou, ChinaShow moreShow less
565
days
The multifaceted role of a-to-i rna editing in tumorigenesis: from coding to noncoding RNAs
Authors
Hussein Sabit; Rawan M. Abdelazeem; Aysha Ghazy; Nouran Mohamed; Shaimaa Abdel-GhanyShow moreShow less
Affiliations
1. Department of Medical Biotechnology, College of Biotechnology, Misr University for Science and Technology, Giza, Egypt; 2. Department of Agriculture Biotechnology, College of Biotechnology, Misr University for Science and Technology, Giza, Egypt; 3. Department of Environmental Biotechnology, College of Biotechnology, Misr University for Science and Technology, Giza, EgyptShow moreShow less
219
days
Metabolic targeting of multiple myeloma using the Warburg Trap
Authors
Nina Hildenbrand; Elena Tripel; Svitlana Melnik; Daniel Strelzov; Alexandra M. Poos; Lukas John; Niels Weinhold; Marc A. Baertsch; Tilman Walker; Burkhard Lehner; Jörg FellenbergShow moreShow less
Affiliations
1. Research Centre for Molecular and Regenerative Orthopaedics, Department of Orthopaedics, Heidelberg University Hospital, Heidelberg, Germany; 2. Department of Orthopaedics, Medical Faculty, Heidelberg University Hospital, Heidelberg University, Heidelberg, Germany; 3. Department of Orthopaedics, Heidelberg University Hospital, Heidelberg, Germany; 4. Heidelberg Myeloma Center, Department of Internal Medicine V, Medical Faculty, Heidelberg University Hospital, Heidelberg University, Heidelberg, Germany; 5. Clinical Cooperation Unit Molecular Hematology/Oncology, Department of Internal Medicine V, Heidelberg University Hospital, Heidelberg University, German Cancer Research Center (DKFZ), Heidelberg, GermanyShow moreShow less
107
days
Refined on-tissue chemical derivatization expands MALDI-MSI capabilities for spatial metabolomics of mammalian organs and metastatic tumors using EDC and 4-APEBA
Authors
Antonia Fecke; Luiza Martins Nascentes Melo; Ann-Cathrin Groba; Gabriele Allies; Feyza Cansiz; Siva Swapna Kasarla; Sven Heiles; Albert Sickmann; Alpaslan Tasdogan; Karl W. SmithShow moreShow less
Affiliations
1. Leibniz-Institut für Analytische Wissenschaften—ISAS—e.V, Dortmund, Germany; 2. Department for Dermatology, Venerology and Allergology, Research Center One Health, University Hospital Essen, German Cancer Consortium, Partner Site Essen & University Alliance Ruhr, Essen, Germany; 3. Lipidomics, Faculty of Chemistry, University of Duisburg-Essen, Essen, Germany; 4. Medizinische Fakultät, Medizinische Proteom-Center (MPC), Ruhr-Universität Bochum, Bochum, GermanyShow moreShow less
394
days
The dual tumor-suppressive mechanisms of STAM in clear cell renal cell carcinoma: EGFR inactivation and autophagy activation via AKT regulation
Authors
Zugen Chen; Leqi Liang; Lei Peng; Menghua Liao; Wenxia Lv; Shan Ao; Zikun Peng; Ming Lei; Di Gu; Yongda Liu; Guohua Zeng; Tuo DengShow moreShow less
Affiliations
1. Department of Urology, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China; 2. Guangdong Provincial Key Laboratory of Urological Diseases, Guangzhou Medical University, Guangzhou, China; 3. Guangdong Engineering Research Center of Urinary Minimally Invasive Surgery Robot and Intelligent Equipment, Guangzhou Medical University, Guangzhou, China; 4. Guangzhou Institute of Urology, Guangzhou Medical University, Guangzhou, China; 5. Guangzhou, ChinaShow moreShow less
FAQ
How long does Cancer Cell International take to review a manuscript?
As of 2026-11-18, CrushSCI has 21 complete review records for Cancer Cell International. The fastest paper went from submission to acceptance in 51 days (Mixed phenotype acute leukemia across lineage boundaries: from classification to clonal biology and precision therapy, received 2026-08-23, accepted 2026-10-13); the slowest took 565 days. The average is 226.5 days and the median is 189 days.
Expert Matching · Case Demo
Turn Your Submission Goalsinto a Verifiable Journal Plan
Share your field, deadline, and author profile. CrushSCI uses real review records to suggest a title direction, shortlist journals, and estimate timelines.
